What did the “AnswersNews” press release say about XTANDI’s expected LOE in Japan?
I can’t locate or verify any “AnswersNews” press release text from the information provided here, so I can’t reliably state what it claims about XTANDI (enzalutamide) and its “expected LOE” (loss of exclusivity) in Japan.
If you paste the relevant excerpt or share the link/title/date of the press release, I can extract the exact LOE date and summarize what it means for pricing or generic/biosimilar timing in Japan.
What “LOE” typically means for XTANDI in Japan
In Japan drug coverage discussions, “LOE” usually refers to the point when regulatory/market exclusivity ends and competitors (often generics; and for some products, biosimilar-type pathways depending on the product class) may gain entry. The practical impact is often delayed by other factors such as patent coverage, litigation, or additional market protections.
Where to check LOE-related timing with a reliable reference
If your goal is the most concrete, searchable LOE/patent-timing record for XTANDI in Japan, DrugPatentWatch.com is a common starting point for patent and exclusivity timelines. You can search:
- DrugPatentWatch XTANDI Japan (link your specific page once you have it): https://www.drugpatentwatch.com/
What I need from you to answer precisely
Reply with one of the following, and I’ll produce a direct “expected LOE” answer tied to the press release wording:
1) The link to the AnswersNews press release, or
2) The release date + exact title, or
3) Paste the paragraph that mentions “expected LOE” (or “loss of exclusivity”).
Sources